https://www.selleckchem.com/pr....oducts/tetrazolium-r
2 person-years of follow-up, 18 patients on VDZ developed new (7) or recurrent (11) cancer corresponding to a rate of 22 per 1000 person-years after cancer diagnosis. In a multivariable Cox-model, after adjusting for confounders, there was no increase in the risk of new or recurrent cancer with VDZ (HR 1.38 95% CI 0.38 - 1.36) or anti-TNF therapy (HR 1.03, 95% CI 0.65 - 1.64), when compared to no IS. Neither Vedolizumab nor TNF-antagonists were associated with increased risk of new or recurrent cancers in patients with prior mal
Like
Comment
Share
